FSD Pharma Inc. | WebDisclosure

Basculer en Français

10472	Companies
220547	Keywords
149874	Articles
116632	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 2 months ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 2 months ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 2 months ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 2 months ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 2 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 2 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 2 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 3 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 3 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 3 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 05/29/2026 at 23:00, 54 minutes ago

The Fresh Factory Reports Q1 2026 Financial Results with 17% Billed Revenue Growth, Completes New Facility Retrofit
Published on 05/29/2026 at 23:00, 54 minutes ago

IBC Advanced Alloys Reports Improved Financial Results for the Quarter Ended March 2026
Published on 05/29/2026 at 22:20, 1 hour 34 minutes ago

Pathfinder Ventures Inc Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 05/29/2026 at 22:05, 1 hour 49 minutes ago

Silver Spruce Resources Inc. Announces Close of Non-Brokered Private Placement
Published on 05/29/2026 at 22:00, 1 hour 54 minutes ago

Findev Inc. Announces Dividend Updates Ex-Dividend Date

View all ACCESSWIRE

EQS Group

Published on 05/29/2026 at 21:42, 2 hours 11 minutes ago

EQS-Adhoc: Consortium reaches definitive agreement to acquire 4finance Holding’s core consumer lending assets and launch Mellenu Holding
Published on 05/29/2026 at 21:30, 2 hours 24 minutes ago

Mutares portfolio company F.lli Ferrari Holding has signed an agreement for the partial sale of its Benelux operations to HMF Group
Published on 05/29/2026 at 20:00, 3 hours 54 minutes ago

Brödernas publishes quarterly report for Jan-Mar 2026
Published on 05/29/2026 at 19:46, 4 hours 7 minutes ago

CPI PROPERTY GROUP publishes financial results for the first quarter of 2026
Published on 05/29/2026 at 19:27, 4 hours 26 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 05/29/2026 at 22:00, 1 hour 54 minutes ago

Information on the Annual Financial Statements 2025
Published on 05/29/2026 at 22:00, 1 hour 54 minutes ago

Information sur les comptes annuels 2025
Published on 05/29/2026 at 21:42, 2 hours 11 minutes ago

Descriptif du programme de rachat d'actions
Published on 05/29/2026 at 18:00, 5 hours 54 minutes ago

Recticel Group versnelt groei in isolatiepanelen met geïntegreerde isothermische oplossingen na overname Isopanel NV
Published on 05/29/2026 at 18:00, 5 hours 54 minutes ago

Recticel Group acquires Isopanel NV to deliver integrated solutions in the cold storage panels market

View all LES ECHOS COMFI WIRE